146 related articles for article (PubMed ID: 20202806)
1. Point-of-care Arkansas method for measuring adherence to treatment with isoniazid.
Guerra RL; Conde MB; Efron A; Loredo C; Bastos G; Chaisson RE; Golub JE
Respir Med; 2010 May; 104(5):754-7. PubMed ID: 20202806
[TBL] [Abstract][Full Text] [Related]
2. Isoniazid/acetylisoniazid urine concentrations: markers of adherence to isoniazid preventive therapy in children.
Amlabu V; Mulligan C; Jele N; Evans A; Gray D; Zar HJ; McIlleron H; Smith P
Int J Tuberc Lung Dis; 2014 May; 18(5):528-30. PubMed ID: 24903787
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the Arkansas method of urine testing for isoniazid in South Africa.
Hanifa Y; Mngadi K; Lewis J; Fielding K; Churchyard G; Grant AD
Int J Tuberc Lung Dis; 2007 Nov; 11(11):1232-6. PubMed ID: 17958987
[TBL] [Abstract][Full Text] [Related]
4. Point-of-care urine tests for smoking status and isoniazid treatment monitoring in adult patients.
Nicolau I; Tian L; Menzies D; Ostiguy G; Pai M
PLoS One; 2012; 7(9):e45913. PubMed ID: 23029310
[TBL] [Abstract][Full Text] [Related]
5. Adherence with isoniazid for prevention of tuberculosis among HIV-infected adults in South Africa.
Szakacs TA; Wilson D; Cameron DW; Clark M; Kocheleff P; Muller FJ; McCarthy AE
BMC Infect Dis; 2006 Jun; 6():97. PubMed ID: 16772037
[TBL] [Abstract][Full Text] [Related]
6. Use of the urine color test to monitor compliance with isoniazid treatment of latent tuberculosis infection.
Eidlitz-Markus T; Zeharia A; Baum G; Mimouni M; Amir J
Chest; 2003 Mar; 123(3):736-9. PubMed ID: 12628871
[TBL] [Abstract][Full Text] [Related]
7. A novel metabolite of antituberculosis therapy demonstrates host activation of isoniazid and formation of the isoniazid-NAD+ adduct.
Mahapatra S; Woolhiser LK; Lenaerts AJ; Johnson JL; Eisenach KD; Joloba ML; Boom WH; Belisle JT
Antimicrob Agents Chemother; 2012 Jan; 56(1):28-35. PubMed ID: 22037847
[TBL] [Abstract][Full Text] [Related]
8. Urine testing to monitor adherence to TB preventive therapy.
Perry S; Hovell MF; Blumberg E; Berg J; Vera A; Sipan C; Kelley N; Moser K; Catanzaro A; Friedman L
J Clin Epidemiol; 2002 Mar; 55(3):235-8. PubMed ID: 11864793
[TBL] [Abstract][Full Text] [Related]
9. A simplified method for detecting isoniazid compliance in patients receiving antituberculosis chemotherapy.
Hashiguchi M; Ohno K; Sakuma A; Hino F; Tanaka T; Ohtsuji M; Matsumoto N; Yanase K; Urae A; Hosogai Y; Sato N; Yazaki A; Matsuda K; Yamazaki K; Rikihisa T
J Clin Pharmacol; 2002 Feb; 42(2):151-6. PubMed ID: 11831537
[TBL] [Abstract][Full Text] [Related]
10. Low level of compliance with tuberculosis treatment in children: monitoring by urine tests.
Palanduz A; Gültekin D; Erdem E; Kayaalp N
Ann Trop Paediatr; 2003 Mar; 23(1):47-50. PubMed ID: 12648324
[TBL] [Abstract][Full Text] [Related]
11. Urine color test to monitor isoniazid compliance: "pissin' in the wind"?
Hollender ES; Ashkin D; Narita M
Chest; 2003 Mar; 123(3):668-70. PubMed ID: 12628857
[No Abstract] [Full Text] [Related]
12. Adherence to tuberculosis preventive therapy measured by urine metabolite testing among people with HIV.
Kendall EA; Durovni B; Martinson NA; Cavalacante S; Masonoke K; Saraceni V; Lebina L; Efron A; Cohn S; Chon S; Chaisson RE; Dowdy DW; Golub JE;
AIDS; 2020 Jan; 34(1):63-71. PubMed ID: 31567163
[TBL] [Abstract][Full Text] [Related]
13. [Modified method for indicating antitubercular agents in the urine in tuberculosis].
Solov'eva AS; Lukomskaia VM
Lab Delo; 1980; (12):756-7. PubMed ID: 6163900
[No Abstract] [Full Text] [Related]
14. Adherence to isoniazid preventive chemotherapy: a prospective community based study.
Marais BJ; van Zyl S; Schaaf HS; van Aardt M; Gie RP; Beyers N
Arch Dis Child; 2006 Sep; 91(9):762-5. PubMed ID: 16737993
[TBL] [Abstract][Full Text] [Related]
15. The value of urine testing for verifying adherence to anti-tuberculosis chemotherapy in children and adults in Uganda.
Meissner PE; Musoke P; Okwera A; Bunn JE; Coulter JB
Int J Tuberc Lung Dis; 2002 Oct; 6(10):903-8. PubMed ID: 12365577
[TBL] [Abstract][Full Text] [Related]
16. Point-of-care urine test for assessing adherence to isoniazid treatment for tuberculosis.
Soobratty MR; Whitfield R; Subramaniam K; Grove G; Carver A; O'Donovan GV; Wu HH; Lee OY; Swaminathan R; Cope GF; Milburn HJ
Eur Respir J; 2014 May; 43(5):1519-22. PubMed ID: 24435008
[No Abstract] [Full Text] [Related]
17. The reliability and practicality of the Arkansas method assay of isoniazid adherence.
Schmitz KE; Hovell MF; Wong CA; Kelley NJ; Nilsen D; Blumberg EJ; Hill LL; Sipan CL; Kolody B; Chatfield DA
Clin Nurs Res; 2010 May; 19(2):131-43. PubMed ID: 20435784
[TBL] [Abstract][Full Text] [Related]
18. [Effects of INH (Isoniazid) inhalation in patients with endobronchial tuberculosis (EBTB)].
Yokota S; Miki K
Kekkaku; 1999 Dec; 74(12):873-7. PubMed ID: 10655693
[TBL] [Abstract][Full Text] [Related]
19. Global Urine Metabolomics in Patients Treated with First-Line Tuberculosis Drugs and Identification of a Novel Metabolite of Ethambutol.
Das MK; Arya R; Debnath S; Debnath R; Lodh A; Bishwal SC; Das A; Nanda RK
Antimicrob Agents Chemother; 2016 Apr; 60(4):2257-64. PubMed ID: 26833163
[TBL] [Abstract][Full Text] [Related]
20. Twelve-Week Rifapentine Plus Isoniazid Versus 9-Month Isoniazid for the Treatment of Latent Tuberculosis in Renal Transplant Candidates.
Simkins J; Abbo LM; Camargo JF; Rosa R; Morris MI
Transplantation; 2017 Jun; 101(6):1468-1472. PubMed ID: 27548035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
